PMS Registry
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
Company Name
Title of Study
Update Date
AbbVie Biopharmaceuticals GmbH Taiwan Branch A Multi-country, Post Marketing Observational Study of DME Patients with Suboptimal Response to anti-VEGF who are initiated with Dexamethasone intravitreal implant (DEX-I) 2024-07-05
Sanofi PROphylactic Efanesoctocog Alfa Therapy Evaluated for Critical Joint Health in Hemophilia A Treatment: The PROTECT-ALT Study 2024-07-05
Novo Nordisk Pharma (Taiwan) Ltd. Multicentre, single-arm, non-interventional regulatory post-marketing surveillance (rPMS) study to evaluate the safety and effectiveness of Saxenda® for weight management in routine clinical practice in Taiwan 2024-07-05
Bayer Taiwan Company Ltd. REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immuno-oncology immune checkpoint inhibitor combination in first-line. 2024-07-05
Janssen Taiwan Multicenter, Post-authorization Safety Study to Collect Disease Outcome Information from Taiwanese Research Participants with Niemann-Pick Disease Type C 2024-07-05
Bayer Taiwan Co., Ltd. FINE-REAL: A non-interventional study providing insights into the use of finerenone in a routine clinical setting 2024-07-05
Pfizer Limited Real world evaluation of COVID-19 burden and nirmatrelvir/ritonavir in Taiwan using National Health Insurance Research Database 2024-07-05
Bristol-Myers Squibb (Taiwan) Ltd. Empliciti® (elotuzumab) Post-marketing Surveillance Study for Patients with Multiple Myeloma in Taiwan 2024-07-05
Sanofi Observational study of atopic dermatitis patients treated with dupilumab in Taiwan 2024-07-05
Sanofi An Observational Study of Enzyme Replacement Therapy-Naïve and Agalsidase beta-Treated Fabry Disease Patients with GLA IVS4+919 G>A Mutation in Taiwan 2024-07-05
   1 2 3 4 5 6 7 8 9